YMDD motif variants detected by Inno-Lipa HBV DR assay in chronic hepatitis B patients during lamivudine therapy;Lamivudin tedavisi alan kronik hepatit B olgularinda Inno-Lipa HBV DR yöntemi ile saptanan YMDD motif deǧişiklikleri

Mikrobiyoloji Bulteni

Volumn 42, Issue 3, 2008, Pages 445-450

  Arslan, Uǧur ^a   Ural, Onur ^a   Findik, Duygu ^a  

^a SELCUK UNIVERSITY   (Turkey)

Author keywords

Hepatitis B virus; Line probe assay (LIPA); Resistance; YMDD mutation

Indexed keywords

ADEFOVIR; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DRUG DERIVATIVE; LAMIVUDINE; PHOSPHONIC ACID DERIVATIVE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS DNA;

ANTIVIRAL RESISTANCE; ARTICLE; BLOOD; CHEMISTRY; DRUG COMBINATION; DRUG EFFECT; GENETICS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; ISOLATION AND PURIFICATION; MUTATION; PROTEIN MOTIF; VIROLOGY;

ADENINE; AMINO ACID MOTIFS; ANTI-HIV AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MUTATION; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE;

EID: 52349103647     PISSN: 03749096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Özdemir D, Kurt H. Hepatit B virusu enfeksiyonlarinin epidemiyolojisi, s: 107-16. Tabak F, Balik I, Tekeli E (ed), Viral Hepatit 2007. 2007, Viral Hepatit Savaşim Derneǧi, Ankara.
2. Akarca US. Kronik B hepatiti tedavisi, s: 190-7. Ustaçelebi Ş, Badur S, Abacioǧlu H (eds), Uluslararasi Katilimli I. Ulusal Viroloji Kongresi, Konferanslar ve Bildiriler Kitabi. 2003, Öncü Basimevi, Ankara.
3. Beşişik F. Kronik B hepatiti tedavisinde nükleozid analoglari, s: 192-202. Tabak F, Balik I, Tekeli E (eds), Viral Hepatit 2007. 2007, Viral Hepatit Savaşim Derneǧi, Ankara.
4. Liaw YF. The current management of HBV drug resistance. J Clin Virol 2005; 34(Suppl 1): 143-4.
5. Zoulim F. Detection of hepatitis B virus resistance to antivirals. J Clin Virol 2001; 21: 243-53.
6. Lok ASF, Zoulim F, Locarnini S, et al. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of Inno-Lipa HBV DR assay. J Clin Microbiol 2002; 40: 3729-34.
7. Bozdayi AM. Hepatit B virus infeksiyonlarinda antiviral ilaç direnci, s: 91-7. IV. Ulusal Moleküler ve Tanisal Mikrobiyoloji Kongre Kitabi. 2006, Ankara Mikrobiyoloji Derneǧi, Ankara.
8. Çakaloǧlu Y. Hepatit B tedavisi: kronik hepatit dişi indikasyonlar, s: 187-9. Ustaçelebi Ş, Badur S, Abacioǧlu H (eds), Uluslararasi Katilimli I. Ulusal Viroloji Kongresi, Konferanslar ve Bildiriler Kitabi. 2003, Öncü Basimevi, Ankara.
9. Yuen MF, Kato T, Mizokami M, et al. Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations. J Hepatol 2003; 39: 850-5.
10. Akarsu M. Şengönöl A, Tankurt E, et al. YMDD motif variants in inactive hepatitis B carriers detected by Inno-Lipa HBV DR assay. J Gastroenterol Hepatol 2006; 21: 1783-8.
11. Li D, Gu HX, Zhang SY, et al. YMDD mutations and genotypes of hepatitis B virus in Northern China. Jpn J Infect Dis 2006, 59: 42-5.
12. Sönmez E. Antiviral direnç monitorizasyonu ve klinik yaran. Klimik Derg 2001; 14: 66-70.
13. Alvarado-Esquivel CA, de la Ascensión Carrera-Gracia M, Conde-González CJ, et al. Genotypic resistance to lamivudine among hepatitis B virus isolates in Mexico. J Antimicrob Chemother 2006; 57: 221-3.
14. Liang WF, Yang DH, Shen YH, Xie YJ, Zhao NF. Types and emergence time of YMDD motif mutation in hepatitis B virus polymerase gene during lamivudine treatment. Zhonghua Gan Zang Bing Za Zhi 2003; 11: 302-4.
15. Eyigün CP. Hepatit B virüsü mutasyonlarinin klinik önemi ve tedaviye etkileri, s: 131-44. Tabak F, Balik I, Tekeli E (ed), Viral Hepatit 2007. 2007, Viral Hepatit Savaşim Derneǧi, Ankara.